Truist analyst David MacDonald raised the firm’s price target on Cigna (CI) to $405 from $385 and keeps a Buy rating on the shares as part of a broader research note on Health Care Services. The firm is updating its models to reflect Q1 results and updated guidance on select names, the analyst tells investors in a research note.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Proposal to cut Medicaid spending aims for GOP middle ground, WSJ says
- Cigna price target raised to $388 from $384 at Guggenheim
- Cigna’s Balanced Risk/Reward Scenario: Strong Earnings with Cautious Outlook
- Cigna price target raised to $386 from $380 at TD Cowen
- Cigna price target raised to $374 from $348 at Piper Sandler